The saftey and efficacy of intradermal injection of type A butulinum toxin in chemotherapy induced peripheral neuropathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200425047202N1

Enrollment

Registered

2020-07-07

Start date

2019-08-23

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induced neuropathy.

Interventions

Intervention 1: injection of 150 units of butulinum toxin type A in 2 ml normal saline at 10 points of palmar side of one hand intradermally. Intervention 2: Control group: no injections.

Eligibility

Sex/Gender

All

Age

18 Years to 69 Years

Inclusion criteria

Inclusion criteria: Chemotherapy induced neuropathy in patients treated with taxans or platinums with grade 2 or more of neuropathy

Exclusion criteria

Exclusion criteria: Lack of cooperation/////// History of neuropathy before chemotherapy History of allergy to the butulinum toxin Local infection of the injection places Rradiculopathy History of mental disease Alcolol or substance abuse Known renal disease History of miastenia gravis Use of aminoglycosides

Design outcomes

Primary

Measure	Time frame
Pain reduction in control arm. Timepoint: before and then 4 and 6 and 8 weeks after the intervention. Method of measurement: VAS and NPS questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtefeh Tutunchi

Shahid Beheshti University of Medical Sciences

tutunchi.md@gmail.com+98 21 4464 8904

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026